According to a latest report by
Coherent Market Insights, the global Companion Animal Arthritis Market size is expected to reach
US$ 7.8 Bn by 2032, from US$ 4.67 Bn in 2025, exhibiting a CAGR of 7.6% during
the forecast period. Arthritis is a common health issue in aging pets,
particularly dogs and cats, leading to joint inflammation, pain, and reduced
mobility. A variety of treatment options are available to help manage these
symptoms. Non-steroidal anti-inflammatory drugs (NSAIDs) are typically the
first line of treatment, with medications like carprofen, deracoxib, and
meloxicam commonly prescribed to reduce pain and inflammation, either orally or
through injections. In addition to medications, some pets benefit from
nutritional supplements. Glucosamine and chondroitin, taken regularly, are
believed to support joint health by promoting cartilage repair and improving
joint function.

Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/6525

 Global
Companion Animal Arthritis Market Key Takeaways

According to Coherent Market Insights
(CMI), the global companion animal arthritis
market size is expected to reach USD 4.67 Bn in 2025 and USD 7.8 Bn by
2032, exhibiting a CAGR of 7.6%.

By animal type, dogs segment is
anticipated to account for nearly two-fifths of the global companion animal arthritis market share in 2025.

North America is likely to retain its
market dominance, holding a prominent share of 35.7% in 2025.

With a projected market share of over
one-fourth in 2025, Asia Pacific remains the second leading market for
companion animal arthritis treatments.

Europe companion animal arthritis
market is expected to witness fastest growth during the assessment period. This
is due to increasing pet adoption and growing awareness of joint health in
animals across nations like the United Kingdom and France.

Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6525

Rising Arthritis Prevalence in
Companion Animals Spurring Market Growth

Coherent Market Insights’ latest companion animal arthritis market analysis offers
insights into major factors driving industry growth. One such prominent growth
driver is the increasing incidence of arthritis in companion animals.

In recent years, there has been a
notable increase in the cases of arthritis, and the trend will likely continue
during the forecast period. This is primarily due to the aging pet population
and increasing rates of obesity in pets.

According to an article published in
the National Library of Medicine, osteoarthritis affects about 20% of all adult
dogs. This surge in arthritis among pets is expected to drive demand for
companion animal arthritis treatments.

Also Read: Canine Arthritis Market
Size, Share, Trends & Opportunities for 2025-2032

High Treatment Costs Limiting Market
Growth

The global
companion animal arthritis market outlook indicates steady future
growth. However, high cost of treatment poses a big challenge to widespread
market expansion.

Arthritis diagnosis and long-term
treatment can be expensive, especially for pet owners with lower incomes. This
cost factor may reduce companion animal
arthritis market demand during the projection period.

Rising Pet Ownership and Humanization
Trend Creating Growth Opportunities

The global rate of pet ownership is
steadily increasing, with more pet owners viewing their animals as family
members. This growing trend of pet humanization is driving increased spending
on pet health and wellness, including the management of chronic conditions like
arthritis. As a result, demand for effective arthritis treatments for companion
animals is rising, creating significant growth opportunities for companion animal arthritis companies.

Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/6525

Emerging Companion Animal Arthritis Market Trends

Rising popularity of joint supplements is a key
growth-shaping trend in the market. Pet owners are increasingly turning to
dietary supplements like glucosamine and omega-3 fatty acids to manage
arthritis symptoms in companion animals. This trend is expected to create
lucrative growth opportunities for manufacturers of companion animal arthritis
therapeutics.

Expansion of pet insurance policies that cover arthritis
treatment, especially in developed nations, is also contributing to sales
growth. These policies are reducing financial burden of pet owners, encouraging
them to seek proper treatment for their companion animals.

Ongoing advancements in veterinary medicine are expected to
provide a strong impetus for companion animal arthritis market growth. Leading
industry players are focusing on developing advanced regenerative therapies
like stem cell therapy and disease-modifying osteoarthritis drugs (DMOADs) to
manage arthritis in pets more effectively.

Monoclonal antibodies (mAbs) are gaining immense traction in
the market due to their high efficacy. They offer targeted pain relief by
neutralizing nerve growth factor. Rising adoption of monoclonal antibody-based
treatments for managing arthritis in companion animals will play a key role in
boosting overall companion animal arthritis
market value.

Also Read: Psoriatic Arthritis
Treatment Market Analysis and Forecast for 2025-2032

Analyst’s View

“The global companion animal arthritis industry is
poised for rapid expansion, owing to increasing pet ownership, rising
prevalence of arthritis in companion animals, and growing trend of pet
humanization,” said senior analyst Ghanshyam Shrivastava.

Current Events and Their Impact on the
Companion Animal Arthritis Market

Event

Description
and Impact

Surge in Post-COVID Pet Adoptions Now Leading to Aging Pet Population

Description: Many pets adopted
during COVID are now entering middle age and showing early signs of
joint degeneration.

Impact: This
demographic shift is increasing demand for early-stage arthritis
interventions, including NSAIDs, joint supplements, weight management,
and physical therapy.

Rising Veterinary Healthcare Expenditure in North America and Western
Europe

Description: Pet parents are spending more per visit, with
wellness-focused owners driving demand for advanced diagnostics and
chronic care management.

Impact: This will likely boost demand for diagnostic
tools like digital radiography and ultrasound, and support market growth
for higher-margin therapeutics such as monoclonal antibodies (mAbs),
regenerative therapies, and long-acting analgesics.

Recent FDA Approval of Librela™ (bedinvetmab) for Dog

Description: Zoetis’ Librela gained major
traction in the U.S., being the first monoclonal antibody specifically
approved for canine osteoarthritis pain.

Impact: This milestone signals a shift
toward targeted biologics, spurring R&D competition in next-gen
arthritis therapies for both dogs and cats.

Competitor
Insights

Key companies in companion animal arthritis market report
include:

–       NexGen Pharmaceuticals

–       Eltech K-Laser s.r.l

–       Vetoquinol

–       Zoetis

–       Norbrook

–       Elanco

–       Boehringer Ingelheim
International GmbH

–       Eltech K-Laser s.r.l

–       Virbac

–       Dechra Pharmaceuticals PLC

–       Ceva

Key Developments

In February 2025, Zoetis Inc. updated the
U.S. label for Librela (bedinvetmab injection), an effective treatment to
control canine osteoarthritis (OA) pain. The company is confident in Librela’s
safety and effectiveness and will immediately implement the updated label to
support vets and pet owners.

In January 2025, Virbac, in collaboration
with Emmyon Inc., launched URSOLYX Soft Chews for canine. This supplement is
specifically formulated to enhance muscle function and strength in dogs that
are aging, active, or recovering.

In July 2024, Dechra Pharmaceuticals
announced plans to acquire Invetx Inc. The move was aimed at boosting the company’s
monoclonal antibody therapeutics pipeline for chronic conditions in dogs and
cats, including areas like atopic dermatitis and osteoarthritis.

Global Companion animal
arthritis Market Detailed Segmentation:

By Animal Type

By Indication

Osteoarthritis
Other Arthritis

By Treatment

Medication

NSAIDs
Monoclonal Antibodies
Others Medications

Supplements
Other Treatment

By Distribution Channel

Veterinary Hospitals & Clinics
Retail Pharmacies
Online Stores
Others

By Region

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Also Read: Companion Animal Vaccine
Market Size, Share & Trend Analysis Report for 2025-2032

Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights
Get Recent News:
https://www.coherentmarketinsights.com/news

About Us:
Coherent Market
Insights leads into data and analytics, audience measurement, consumer
behaviors, and market trend analysis. From shorter dispatch to in-depth
insights, CMI has exceled in offering research, analytics, and consumer-focused
shifts for nearly a decade. With cutting-edge syndicated tools and custom-made
research services, we empower businesses to move in the direction of growth. We
are multifunctional in our work scope and have 450+ seasoned consultants,
analysts, and researchers across 26+ industries spread out in 32+ countries.

Contact Us:
Mr. Shah
Coherent Market Insights
533 Airport Boulevard,
Suite 400, Burlingame,
CA 94010, United States
US: + 12524771362
UK: +442039578553
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
For Latest Update Follow Us:
LinkedIn | Facebook | Twitter